Pentaflucin, 5 g 10 pcs

Pentaflucin is a combined medicine with antipyretic and anti-inflammatory effects. Paracetamol has antipyretic and analgesic effects.

A non-narcotic analgesic, blocks COX1 and COX2 mainly in the CNS, affecting the centers of pain and thermoregulation. In inflamed tissues cellular peroxidases neutralize the effect of paracetamol on COX, which explains the almost complete lack of anti-inflammatory effect.

Ascorbic acid plays an important role in the regulation of redox processes, carbohydrate metabolism, blood coagulation, tissue regeneration, increases the body’s resistance.

Diphenhydramine has antihistamine and anti-inflammatory, sedative and hypnotic effect. Calcium gluconate is a regulator of calcium and phosphorus metabolism. Rutosine reduces capillary permeability and fragility, has antioxidant properties.

Indications

Hyperthermia in colds and other infectious and inflammatory diseases.

Active ingredient

Composition

1 sachet (5 g) contains:

Active ingredients:

Excipients:
povidone (polyvinylpyrrolidone) – 0.0174 g sucrose (sugar) – 3.9426 g saccharin (saccharin soluble) – 0.050 g citric acid – 0.050 g.

How to take, the dosage

Pentaflucin is taken orally after meals, 1 sachet 3-4 times a day for 3-5 days. Dissolve 1 sachet of Pentaflucin in 1/2 cup of hot water (a slight sediment in the glass is allowed).

The freshly prepared solution should be used.

Interaction

Combination of the drug with barbiturates, anticonvulsants, phenytoin, carbamazepine, rifampicin, zidovudine and other inducers of microsomal liver enzymes should be avoided.

Paracetamol: reduces the effectiveness of uricosuric drugs. Concomitant use of paracetamol in high doses increases the effect of anticoagulant drugs (decrease in the synthesis of procoagulant factors in the liver).

Ethanol promotes the development of acute pancreatitis.

Long-term co-use of paracetamol and other non-steroidal anti-inflammatory drugs increases the risk of “analgesic” nephropathy and renal papillary necrosis, the onset of terminal renal failure.

Diflunisal increases the plasma concentration of paracetamol by 50%, a risk of hepatotoxicity.

Myelotoxic drugs increase the manifestation of hematotoxicity of the drug.

Caffeine: in co-administration of caffeine with cimetidine, oral contraceptives, ciprofloxacin, norfloxacin – reduction of caffeine metabolism in the liver (delayed excretion and increased blood concentrations). Mexiletine – reduces caffeine excretion by up to 50%; nicotine – increases caffeine excretion rate.

Monoamine oxidase inhibitors, furazolidone, procarbazine, and selegiline-large doses of caffeine can cause dangerous cardiac arrhythmias or markedly increased blood pressure.

Accelerates absorption and enhances the effect of cardiac glycosides and increases their toxicity.

The co-use of caffeine with beta-adrenoblockers may lead to mutual suppression of therapeutic effects; with adrenergic bronchodilators – to additional central nervous system stimulation and other additive toxic effects.

Caffeine may decrease clearance of theophylline and possibly other xanthines, increasing the possibility of additive pharmacodynamic and toxic effects.

Ascorbic acid: increases the blood concentration of benzylpenicillin and tetracyclines.
At a dose of 1 g / day increases the bioavailability of ethinylestradiol (including those included in oral contraceptives).

Decreases the effectiveness of heparin and indirect anticoagulants. Improves intestinal absorption of iron preparations (converts trivalent iron to divalent iron); may increase iron excretion if used concomitantly with deferoxamine.

Acetylsalicylic acid (ASA), oral contraceptives, fresh juices and alkaline drinking reduce absorption and assimilation of ascorbic acid. ‘

Concomitant use with ASA increases urinary excretion of ascorbic acid and decreases excretion of ASA. Asc reduces the absorption of ascorbic acid by about 30%.

It increases the risk of crystalluria when treated with salicylates and short-acting sulfonamides, slows renal excretion of acids, increases excretion of drugs with an alkaline reaction (including alkaloids), reduces the blood concentration of oral contraceptives.

Concomitant use decreases the chronotropic effect of isoprenaline.

Calcium gluconate: Concomitant use with quinidine may slow intraventricular conduction and increase quinidine toxicity.

It forms insoluble complexes with tetracycline antibiotics (reduces the antibacterial effect).

It slows down absorption of tetracyclines, digoxin, and oral iron drugs (interval between doses should be at least 2 hours).

In combination with thiazide diuretics may increase hypercalcemia, decrease the effect of calcitonin in hypercalcemia. Reduces the bioavailability of phenytoin.

Pharmaceutically incompatible with carbonates, salicylates, sulfates (forms insoluble or hardly soluble calcium salts).,
Reduces effect of “slow” calcium channel blockers.

Rutoside: pharmacological effect is enhanced by ascorbic acid.

Special Instructions

During treatment, caution should be exercised when driving motor vehicles and engaging in potentially hazardous activities requiring increased concentration and quick psychomotor reactions.

Contraindications

With caution

In Gilbert syndrome (constitutional hyperbilirubinemia). The drug contains sugar (1 sachet contains 0.33 IU of sugar), which should be taken into account by patients with diabetes.

Side effects

In the recommended dosage, adverse reactions are rare. Sometimes there may be skin allergic reactions, nausea, vomiting, headache, general weakness, dizziness.

Ascorbic acid:
Urinary system disorders: moderate pollakiuria (when taking a dose of more than 600 mg/day), with prolonged use of high doses -tiperoxaluria, nephrolithiasis (from calcium oxalate), damage to the glomerular apparatus of the kidneys.

Digestive system disorders: irritation of the mucosa of the gastrointestinal tract.

Allergic reactions: skin rash, skin hyperemia.

Others: inhibition of pancreatic insular apparatus function (hyperglycemia, glucosuria).

Calcium gluconate:
Digestive system: constipation, gastrointestinal mucosa irritation.

Caffeine:
Nervous system: agitation, anxiety, tremor, anxiety, headache, dizziness, increased reflexes, tachypnea, insomnia. Cardiovascular system: palpitations, tachycardia, arrhythmias, increased blood pressure.

Digestive system disorders: nausea, vomiting, aggravation of peptic ulcer disease.

Paracetamol:
Digestive system disorders: nausea, epigastric pain.

Hematopoietic system: anemia, thrombocytopenia, methemoglobinemia.

Allergic reactions: skin rash, itching, urticaria, angioedema.

Hepatotoxic and nephrotoxic effects are possible with long-term use in high doses.

Rutozide:
Allergic reactions: skin rash

Digestive system: nausea, diarrhea, heartburn.

Nervous system disorders: headache.

Cardiovascular system: blood rushes to the face.

If any of the side effects listed in the instructions worsen, or if you notice any other side effects not listed in the instructions, tell your doctor.

Overdose

Treatment: the victim should do gastric lavage, prescribe t adsorbents (activated charcoal) and consult a doctor.

Symptomatic therapy: administration of donators of SH-groups and, precursors of glutathione synthesis – methionine within 8-9 hours after overdose and acetylcysteine – within 8 hours. The need for additional therapeutic measures (further methionine administration, intravenous acetylcysteine) is determined depending on the concentration of paracetamol in the blood, as well as on the time elapsed after its administration.